Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Recombinant Velosulin BR approved in U.S. for diabetes

July 26, 1999

Lanosterol synthase inhibitors under study at Boehringer Ingelheim

July 23, 1999

CRP inhibition as a potential new target for lipid-lowering drugs

July 21, 1999

First report of in vivo efficacy of nonthiazolidinedione PPAR-gamma activator

July 21, 1999

Collaborative research at HMR and Genentech yields new vitronectin receptor antagonists

July 21, 1999

Effective hypoglycemic agents arise from U.S.-French collaborative effort

July 20, 1999

Intranasal apomorphine to enter efficacy studies for erectile dysfunction by year end

July 19, 1999

FDA clears pioglitazone for type II diabetes

July 19, 1999

SB identifies nonprodrug integrin antagonist with excellent oral bioavailability

July 16, 1999

Novel antidiabetic pyridines and pyrimidines described by Novo Nordisk

July 16, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...